Literature DB >> 6628504

Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism.

M Døssing, H Pilsgaard, B Rasmussen, H E Poulsen.   

Abstract

Four healthy subjects were investigated weekly for 14 weeks by the antipyrine one sample saliva test, the 48-h urinary excretion of major antipyrine metabolites and the 2-h aminopyrine breath test before, during and after stimulation and inhibition of drug metabolism with phenobarbital and cimetidine, respectively. The phenobarbital-induced enhancement of antipyrine clearance (1.33-2.03 times) and of the aminopyrine breath test (0.94-1.19 times) occurred one week after beginning drug administration and persisted for 10 days after its cessation. The cimetidine-related inhibition of antipyrine clearance (0.62-0.85 times) and of the aminopyrine breath test (0.52-0.93 times) was observed 24 h after beginning cimetidine administration and subsided within two days after the last dose. During enhancement and inhibition the clearance of antipyrine to 3-hydroxymethyl-, 4-hydroxy- and norantipyrine varied as the total antipyrine clearance. The intraindividual variation in antipyrine clearance was 6-8%, and the corresponding variation in urinary excretion of antipyrine metabolites was 10-20%. It is concluded that the influence of phenobarbital and cimetidine on hepatic microsomal enzyme activity can be monitored simply by measurement of the blood concentration of the drug. Whether this simple relationship applies to other microsomally mediated drug interactions requires further evaluation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6628504     DOI: 10.1007/bf00543794

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  37 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

Review 2.  Nutrition and chemical biotransformations in man.

Authors:  A H Conney; E J Pantuck; R Kuntzman; A Kappas; K E Anderson; A P Alvares
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

3.  Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis.

Authors:  G W Hepner; E S Vesell
Journal:  N Engl J Med       Date:  1974-12-26       Impact factor: 91.245

4.  Impairment of drug metabolism by disulfiram in man.

Authors:  E S Vesell; G T Passananti; C H Lee
Journal:  Clin Pharmacol Ther       Date:  1971 Sep-Oct       Impact factor: 6.875

5.  "Homogeneous" enzyme immunoassay. A new immunochemical technique.

Authors:  K E Rubenstein; R S Schneider; E F Ullman
Journal:  Biochem Biophys Res Commun       Date:  1972-05-26       Impact factor: 3.575

6.  Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Authors:  M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

7.  Stimulatory effect of brussels sprouts and cabbage on human drug metabolism.

Authors:  E J Pantuck; C B Pantuck; W A Garland; B H Min; L W Wattenberg; K E Anderson; A Kappas; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

8.  Differential effects of enzyme induction on antipyrine metabolite formation.

Authors:  M Danhof; R M Verbeek; C J van Boxtel; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

Review 9.  Inhibitors of Cytochrome P-450s and their mechanism of action.

Authors:  B Testa; P Jenner
Journal:  Drug Metab Rev       Date:  1981       Impact factor: 4.518

10.  Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test.

Authors:  P J Neuvonen; R A Tokola; M Kaste
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more
  23 in total

Review 1.  Drug interactions at the renal level. Implications for drug development.

Authors:  P L Bonate; K Reith; S Weir
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

2.  Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance.

Authors:  H Perrild; L Kayser; H E Poulsen; L Skovsted; B Jørgensen; J M Hansen
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

3.  Inhibition and induction of metronidazole and antipyrine metabolism.

Authors:  S Loft; J Sonne; H E Poulsen; K T Petersen; B G Jørgensen; M Døssing
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Antipyrine kinetics in liver disease and liver transplantation.

Authors:  M U Mehta; R Venkataramanan; G J Burckart; R J Ptachcinski; S L Yang; J A Gray; D H Van Thiel; T E Starzl
Journal:  Clin Pharmacol Ther       Date:  1986-04       Impact factor: 6.875

5.  Inhibition of antipyrine elimination by disulfiram and cimetidine: the effect of concomitant administration.

Authors:  S Loft; J Sonne; H Pilsgaard; M Døssing; E Poulsen
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

6.  Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide.

Authors:  U Klotz; P Arvela; B Rosenkranz
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 7.  Noninvasive assessment of microsomal enzyme activity in occupational medicine: present state of knowledge and future perspectives.

Authors:  M Døssing
Journal:  Int Arch Occup Environ Health       Date:  1984       Impact factor: 3.015

8.  Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.

Authors:  P N Patsalos; J S Duncan; S D Shorvon
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

Review 9.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

10.  Comparison of trimethadione and antipyrine as indicators of oxidative drug metabolizing capacity in man.

Authors:  E Tanaka; K Nakamura
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.